emicerfont

Small moleculeexperimental

Emicerfont (GW-876,008) is a drug developed by GlaxoSmithKline which acts as a CRF-1 antagonist. Corticotropin releasing factor (CRF), also known as Corticotropin releasing hormone, is an endogenous peptide hormone which is released in response to various triggers such as chronic stress, and activates the two corticotropin-releasing hormone receptors: CRF1 and CRF2. This then triggers the release of corticotropin (ACTH), another hormone which is involved in the physiological response to stress. — Wikipedia

Clinical trial activity

10 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
6
Phase 2
4
Phase 3
0
Phase 4
0

Earliest trial started Nov 1, 2006 (NCT00429728)

Timeline

2000s

  1. Jan 1, 2006

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2006

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

COc1ccc(N2CCc3c(-n4ccc(N5CCNC5=O)n4)cc(C)nc32)c(C)c1
Mol. weight
404.47 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • emicerfont
  • emicerfont
  • emicerfont
  • gw876008
  • gw876008
  • gw876008
  • gw876008
  • gw 876008
  • gw-876008
  • gw876008x
  • gw876008x

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00511563Phase 2Aug 1, 2007GlaxoSmithKline
NCT00508911Phase 1Jun 1, 2007GlaxoSmithKline
NCT00555139Phase 1Mar 1, 2007GlaxoSmithKline
NCT00424697Phase 1Mar 1, 2007GlaxoSmithKline
NCT00423761Phase 1Dec 1, 2006GlaxoSmithKline
NCT00385099Phase 2Dec 1, 2006GlaxoSmithKline
NCT00376896Phase 1Nov 1, 2006GlaxoSmithKline
NCT00429728Phase 1Nov 1, 2006GlaxoSmithKline
NCT00397722Phase 2Nov 1, 2006GlaxoSmithKline
NCT00421707Phase 2Nov 1, 2006GlaxoSmithKline
Showing 10 of 10 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GlaxoSmithKlineFor profit101022006
1 organizations
Page 1 / 1